239 related articles for article (PubMed ID: 34778941)
41. Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.
Fan L; Wang L; Cao L; Zhu H; Xu W; Li J
Front Med; 2022 Apr; 16(2):285-294. PubMed ID: 34727319
[TBL] [Abstract][Full Text] [Related]
42. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Gupta S; Seethapathy H; Strohbehn IA; Frigault MJ; O'Donnell EK; Jacobson CA; Motwani SS; Parikh SM; Curhan GC; Reynolds KL; Leaf DE; Sise ME
Am J Kidney Dis; 2020 Jul; 76(1):63-71. PubMed ID: 31973908
[TBL] [Abstract][Full Text] [Related]
43. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
Makita S; Imaizumi K; Kurosawa S; Tobinai K
Drugs Context; 2019; 8():212567. PubMed ID: 30815024
[TBL] [Abstract][Full Text] [Related]
44. Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?
Chadha J; Hussein S; Zhan Y; Shulman J; Brody J; Ratner L; Steinberg A
Int J Hematol Oncol Stem Cell Res; 2019 Apr; 13(2):102-107. PubMed ID: 31372204
[TBL] [Abstract][Full Text] [Related]
45. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
46. Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
Kanwal B
Cureus; 2021 Jul; 13(7):e16307. PubMed ID: 34277304
[TBL] [Abstract][Full Text] [Related]
47. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
[TBL] [Abstract][Full Text] [Related]
48. Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report.
Niu ZY; Sun L; Wen SP; Song ZR; Xing L; Wang Y; Li JQ; Zhang XJ; Wang FX
World J Clin Cases; 2021 Apr; 9(10):2394-2399. PubMed ID: 33869619
[TBL] [Abstract][Full Text] [Related]
49. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Yuen C; Rezania K; Kelly T; Bishop MR
Immunotherapy; 2021 Oct; 13(15):1261-1269. PubMed ID: 34558978
[TBL] [Abstract][Full Text] [Related]
50. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
51. Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".
Kesireddy M; Lunning M
Oncology (Williston Park); 2022 Jun; 36(6):366-375. PubMed ID: 35723942
[TBL] [Abstract][Full Text] [Related]
52. Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
He J; Zou R; Kang L; Yu L; Wang P; Shao Y; Liang J; Wu D; Jin Z; Qu C
Front Oncol; 2023; 13():1283194. PubMed ID: 38090479
[TBL] [Abstract][Full Text] [Related]
53. CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report.
Chen L; Xu B; Liu W; Wang D; Xu J; Mao X; Xiao M; Zhou J; Xiao Y
Onco Targets Ther; 2022; 15():361-366. PubMed ID: 35422632
[TBL] [Abstract][Full Text] [Related]
54. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Nuvvula S; Dahiya S; Patel SA
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
[TBL] [Abstract][Full Text] [Related]
55. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
[TBL] [Abstract][Full Text] [Related]
56. CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions.
Jommi C; Bramanti S; Pani M; Ghirardini A; Santoro A
Front Pharmacol; 2022; 13():915342. PubMed ID: 35837293
[TBL] [Abstract][Full Text] [Related]
57. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
58. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
59. Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
Frontzek F; Karsten I; Schmitz N; Lenz G
Ther Adv Hematol; 2022; 13():20406207221103321. PubMed ID: 35785244
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
